Skip to content
Screener

Mirum Pharmaceuticals, Inc. MIRM Livmarli — Product sales, net

Other product segments

Bile Acid Medicines
$47.52M+19.9%

Similar metrics at other companies

Vericel logo
VCELEpicel — Product sales, net
$10.4M+20.8%
Vericel logo
VCELBiopsy kits — Product sales, net
$614K-4.4%
Vericel logo
VCELMACI implants, kits, and instruments — Product sales, net
$49.89M+26.5%
Vericel logo
VCELM A C I Implants and kits — Product sales, net
$65.51M+22.5%
Pacira BioSciences, Inc. logo
PCRXNet product sales — Total net product sales
$177.38M+5.8%
Spectrum Brands Holdings logo
SPBProduct sales — Net Sales
$704M+5.1%

Other financials

Income statement

See full
Revenue$176.2M+37.9%
Operating income-$42.5M-753%
Net income-$67.2M-1,047%
EPS (diluted)-$1.06-783%

Balance sheet

See full
Cash & equivalents$262.7M+39.4%
Total debt$12.9M+29.2%
Total equity-$10.4M-104%
Total assets$1.0B+44.0%

Cash flow

See full
Operating cash flow-$44.3M-468%
CapEx$23.0K-81.7%
Free cash flow-$44.3M-472%

Valuation

See full
Market cap$6.45B+144%
Enterprise value$6.2B+151%
P/S10.4×+4.3×

Profitability

See full
Operating margin-134.9%-151pp
Net margin-139.2%-156pp
FCF margin-37%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Mirum Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001759425-26-000045
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Product sales, net:
Livmarli$128,721$88,160$242,525$161,384
Bile Acid Medicines47,52239,62593,60077,986
Total product sales, net$176,243$127,785$336,125$239,370

Item 1. Financial Statements (Unaudited)

FAQ

What is Mirum Pharmaceuticals, Inc.'s livmarli — product sales, net?
Mirum Pharmaceuticals, Inc. (MIRM) reported livmarli — product sales, net of $128.72M in Q2 2026.
How has Mirum Pharmaceuticals, Inc.'s livmarli — product sales, net changed year-over-year?
Mirum Pharmaceuticals, Inc.'s livmarli — product sales, net increased by 46.0% year-over-year, from $88.16M to $128.72M.
What is the long-term trend for Mirum Pharmaceuticals, Inc.'s livmarli — product sales, net?
Over 3 years (2021 to 2025), Mirum Pharmaceuticals, Inc.'s livmarli — product sales, net has grown at a 385.9% compound annual growth rate (CAGR), from $3.14M to $360.01M.
What does livmarli — product sales, net mean?
Represents the total revenue generated from the sale of a specific pharmaceutical product after accounting for returns, allowances, and rebates. This metric is a primary indicator of market adoption and commercial success for a therapeutic asset.

Ask your AI about Mirum Pharmaceuticals, Inc.'s livmarli — product sales, net.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude